ANI Pharmaceuticals, Inc. (ANIP) P/E Ratio History
Deep ValueTrading at 23.9x · 10th percentile of 5-year range · Significant discount to historical valuation · Data 2006–2026
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, ANI Pharmaceuticals, Inc. (ANIP) trades at a price-to-earnings ratio of 23.9x, with a stock price of $79.49 and trailing twelve-month earnings per share of $4.16.
The current P/E is 93% below its 5-year average of 351.9x. Over the past five years, ANIP's P/E has ranged from a low of 19.5x to a high of 5654.0x, placing the current valuation at the 10th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, ANIP is roughly in line with its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, ANIP trades roughly in line with the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ANIP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ANIP Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ANIP P/E vs Peers
Complex generics and injectables peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $5B | 73.7 | - | +158% | |
| $7B | 30.5 | - | -22% | |
| $1B | 26.8 | 3.58Best | +1883%Best | |
| $2B | 52.4 | - | +120% | |
| $90B | 19.6Lowest | - | +49% | |
| $52B | 34.4 | - | +87% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ANIP Historical P/E Data (2006–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $76.90 | $3.94 | 19.5x | -92% |
| FY2025 Q4 | Dec 31 2025 | $78.94 | $3.35 | 23.6x | -90% |
| FY2025 Q3 | - | $91.60 | $1.63 | 56.2x | -76% |
| FY2024 Q2 | Jun 30 2024 | $63.68 | $1.23 | 51.8x | -78% |
| FY2024 Q1 | Mar 31 2024 | $69.13 | $1.70 | 40.7x | -83% |
| FY2023 Q4 | Dec 31 2023 | $55.14 | $0.93 | 59.2x | -75% |
| FY2023 Q3 | Sep 30 2023 | $58.06 | $0.61 | 94.8x | -60% |
| FY2019 Q4 | - | $61.67 | $0.48 | 128.5x | -46% |
| FY2019 Q3 | Sep 30 2019 | $72.88 | $1.35 | 54.0x | -77% |
| FY2019 Q2 | Jun 30 2019 | $82.20 | $1.45 | 56.7x | -76% |
| FY2019 Q1 | Mar 31 2019 | $70.54 | $1.15 | 61.3x | -74% |
| FY2018 Q4 | Dec 31 2018 | $45.02 | $1.30 | 34.6x | -85% |
| FY2018 Q3 | Sep 30 2018 | $56.54 | $0.01 | 5654.0x | +2291% |
| FY2017 Q3 | Sep 30 2017 | $52.49 | $0.64 | 82.4x | -65% |
| FY2017 Q2 | Jun 30 2017 | $46.80 | $0.46 | 102.4x | -57% |
| FY2017 Q1 | Mar 31 2017 | $49.51 | $0.33 | 151.3x | -36% |
| FY2016 Q4 | Dec 31 2016 | $60.62 | $0.35 | 174.6x | -26% |
| FY2016 Q3 | Sep 30 2016 | $66.35 | $0.69 | 96.2x | -59% |
| FY2016 Q2 | - | $55.82 | $0.86 | 64.9x | -73% |
| FY2016 Q1 | - | $33.66 | $1.07 | 31.5x | -87% |
| FY2015 Q4 | - | $45.13 | $1.33 | 33.9x | -86% |
| FY2015 Q3 | Sep 30 2015 | $39.51 | $2.90 | 13.6x | -94% |
| FY2015 Q2 | - | $62.05 | $3.10 | 20.0x | -92% |
| FY2015 Q1 | - | $62.55 | $2.58 | 24.2x | -90% |
| FY2014 Q4 | Dec 31 2014 | $56.39 | $2.53 | 22.3x | -91% |
| FY2014 Q3 | - | $28.28 | $1.07 | 26.4x | -89% |
| FY2014 Q2 | Jun 30 2014 | $34.44 | $0.86 | 40.0x | -83% |
| FY2007 Q3 | Sep 30 2007 | $208.80 | $6.81 | 30.7x | -87% |
| FY2007 Q2 | Jun 30 2007 | $228.24 | $7.86 | 29.0x | -88% |
| FY2007 Q1 | Mar 31 2007 | $214.92 | $7.38 | 29.1x | -88% |
| FY2006 Q4 | Dec 31 2006 | $99.72 | $4.20 | 23.7x | -90% |
Average P/E for displayed period: 236.5x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
20+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ANIP — Frequently Asked Questions
Quick answers to the most common questions about buying ANIP stock.
What is ANIP's P/E ratio?
ANI Pharmaceuticals, Inc. (ANIP) trailing twelve-month P/E ratio is 23.9x, based on TTM diluted EPS of $4.16. The 5-year average P/E is 351.9x and the historical range spans 19.5x to 5654.0x.
Is ANIP stock overvalued or undervalued?
ANIP trades at 23.9x P/E, below its 5-year average of 351.9x. At the 10th percentile of its historical range (19.5x–5654.0x), the stock is priced at a discount to its own history.
Is ANIP stock expensive?
No, ANIP is not expensive on a historical basis. The current P/E of 23.9x is below the 5-year average of 351.9x and sits at the 10th percentile of its valuation range.
What is ANIP's historical P/E range?
Over the past 5 years, ANIP's P/E ratio has ranged from 19.5x to 5654.0x, with a median of 61.3x and an average of 351.9x. The current P/E of 23.9x places the stock at the 10th percentile of this range. Full historical data spans 2006–2026.
How does ANIP's P/E compare to the S&P 500?
ANIP trades at 23.9x P/E versus the S&P 500 median of 24.4x. The 2% discount to the market suggests lower growth expectations or perceived higher risk.
How does ANIP's valuation compare to Healthcare peers?
ANI Pharmaceuticals, Inc. P/E of 23.9x compares to the Healthcare sector median of 22.1x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ANIP's PEG ratio?
ANIP PEG ratio is N/A, based on a P/E of 23.9x and EPS growth of 419.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ANIP's earnings yield?
ANIP earnings yield is 4.18%, the inverse of its 23.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.